Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Dahlöf, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3

Dahlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705, 10.1016/S0895-7061(97)88956-X

Dahlöf, 1998, Characteristics of 9,194 patients with left ventricular hypertrophy: the LIFE Study, Hypertension, 32, 989, 10.1161/01.HYP.32.6.989

Kjeldsen, 2000, Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE Study, Am J Hypertens, 13, 899, 10.1016/S0895-7061(00)00280-6

Kannel, 1979, Diabetes and cardiovascular risk factors in the Framingham study, Circulation, 59, 8, 10.1161/01.CIR.59.1.8

Stamler, 1993, Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434

Zimmet, 2001, Global and societal implications of the diabetic epidemic, Nature, 414, 782, 10.1038/414782a

1985

Andersson, 1991, An updated coronary risk profile: a statement for health professionals, Circulation, 83, 356, 10.1161/01.CIR.83.1.356

Curb, 1996, Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older patients with isolated systolic hypertension, JAMA, 276, 1886, 10.1001/jama.1996.03540230036032

Tatti, 1998, Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM, Diabetes Care, 21, 597, 10.2337/diacare.21.4.597

Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension, N Engl J Med, 338, 645, 10.1056/NEJM199803053381003

1998, Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39, BMJ, 317, 713, 10.1136/bmj.317.7160.713

Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0

Tuomilehto, 1999, Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension, N Engl J Med, 340, 677, 10.1056/NEJM199903043400902

Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6

2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7

Lindholm, 2000, Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2, J Hypertens, 18, 1671, 10.1097/00004872-200018110-00020

Hansson, 2000, Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study, Lancet, 356, 359, 10.1016/S0140-6736(00)02526-5

Brown, 2000, Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT), Lancet, 356, 366, 10.1016/S0140-6736(00)02527-7

Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301

Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161

Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303

Devereux, 2000, Impact of diabetes on cardiac structure and function: the Strong Heart Study, Circulation, 101, 2271, 10.1161/01.CIR.101.19.2271

Palmieri, 2001, Impact of type II diabetes on left ventricular geometry and function: the Hypertension Genetic Epidemiology Network (HyperGEN) Study, Circulation, 103, 102, 10.1161/01.CIR.103.1.102

Bella, 2001, Separate and joint effects of hypertension and diabetes mellitus on left ventricular structure and function: the Strong Heart Study, Am J Cardiol, 87, 1260, 10.1016/S0002-9149(01)01516-8

Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A

1999, 1999 World Health Organisation-International Society of Hypertension guidelines for the management of hypertension, J Hypertens, 17, 151

Weir, 1999, The renin-angiotensin-aldosterone system: a specific target for hypertension management, Am J Hypertension, 12, 205S, 10.1016/S0895-7061(99)00103-X

2002, Diabetic nephropathy, Diabetes Care, 25, S85